Oncotarget on T-cell recognition and immune checkpoints argues that various components in the human system play vital roles in protecting people from cancer. T-Cell dependent immune response to tumor antigens depicts a very important function in tumor immune surveillance. The critical effector cells of adaptive antitumor immunity are the activated cytotoxic t-lymphocytes. Tumors develop numerous techniques to prevent detection and elimination by the home immune system.
A developed knowledge of the particular activators and inhibitors of the immune system have brought about therapeutic developments and advancements in cancer treatment. There are several targetable immune checkpoint blockade molecules at the present time. Lymphocyte activation gene 3 works to significantly lower the immune response through regulatory cells and direct effects on the cells. Visit Oncotarget’s profile page at Facebook.
The T-cell immunoglobulin domain and cumin domain -3 accelerates cell death to negatively control Tcl functions once it binds the ligand galectin-9. PDI -1 and CTLA-4 are the only ones that have proved to be clinically effective among all other inhibitory checkpoint molecules.
Oncotarget will now be publishing two issues a week which will be available in PubMed and other highly profile scientific Research Indexes and Archives.
It is an exceptional multidisciplinary bio-medical magazine. It works uniformly with all the extraordinary profile methodical indexes and collections to make scientific results vastly and largely available and accessible to the investigators in the health field. It also focuses on providing legitimate information practitioners in different medical fields and the public in general. It will therefore be publishing two articles a week in order to trigger the indexing procedural measures and actions. Learn more at researchgate.net
Articles will appear in PubMed perpetually once they have been attached the page and issue statistics. It offers general research covering topics on oncology like immunology and aging, pathology and chromosomes among others. It has published numerous volumes and issues since its establishment. The organization gives every published paper a direct object identifier and applies the necessary approvals of the committee on public integrity to all published and cited works in general. It looks forward to wide scale publication of information on bio-medical research and other key fields to the present generation.
Learn more: https://www.ncbi.nlm.nih.gov/pmc/journals/1558/
Eric lefkofsky is the Co-founder of Tempus and currently lives in Chicago, USA. Tempus is a biotechnology organization that deals in the therapy of cancer convalescents. Additionally, the company also investigates therapeutic and molecular information and distributes genomic sequencing services helping doctors to make real-time, information-driven conclusions. Also, the main aim of the Tempus is to modernize cancer therapy, enabling convalescents to get treatment according to the data obtained from previous patients. This, therefore, improves the quality of services being provided by the firm. As the CEO, Eric is devoted to spreading the organization’s influence locally, nationally, and internationally. Besides, Mr Lefkofsky is also dedicated to bettering the firm’s expertise on the treatment of cancer. Consequently, increasing the company’s impact on the society.
Other than Tempus, Eric Lefkofsky has also co-founded other organizations. These organizations include Echo Global Logistics (a key provider of technology-enabled transportation, and supply chain management service), and lightbank (a capital company dealing in investments in disruptive technology firms). Also, others include Groupon (a worldwide e-commerce marketplace), and InnerWorkings (a service provider in print media). Apart from business activities, Eric is also a philanthropist using most of his resources on various charitable endeavors. In 2006, Eric Lefkofsky founded the Lefkofsky Family Foundation together with his Liz. The aim of the Foundation is to fund the resources required in bettering arts and culture, healthcare, fundamental human rights, and education in the society. Click here to know more.
In a recent conference in San Diego, at the Fortune Brainstorm Health, Eric lefkofsky said that convalescent data was available, but there were insufficient sources that would combine both therapeutic data with genomic information. He also stated that today’s medical system lacked information about various things that are fundamental for cancer patients to get treatment successfully. Eric added that apart from collecting molecular information, clinical information is also essential. Additionally, doctors are required to have both therapeutic and outcome response information. Therefore other than RNA and DNA makeup, doctors should also have knowledge on which therapies they are on and how they are responding. Eric added that his aim was to get many individuals working on neurological disorders and those starting in oncology to use Tempus’ platform to collect data for analysis.